EP Patent

EP4093397A1 — Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)

Assigned to Principia Biopharma Inc · Expires 2022-11-30 · 3y expired

What this patent protects

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase ("BTK") inhibitors for treatment of subjects with relapsing multiple sclerosis.

USPTO Abstract

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase ("BTK") inhibitors for treatment of subjects with relapsing multiple sclerosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP4093397A1
Jurisdiction
EP
Classification
—
Expires
2022-11-30
Drug substance claim
No
Drug product claim
No
Assignee
Principia Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.